Substantial progresshas been made in therapeutics for nonhospitalizedpatientswithCOVID-
19, butsupplyofand access to treatment remain limited. This Viewpoint summarizes currently …

We assessed the in vitro antiviral activity of remdesivir and its parent nucleoside GS-441524,
molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor …

Variants of SARS-CoV-2 have become a major public health concern due to increased
transmissibility, and escape from natural immunity, vaccine protection, and monoclonal …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged to cause
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …

Dear Editor, Since the first outbreak in late 2019, the RNA genome of SARS-CoV-2 has
been undergoing constant evolution. This is largely attributed to the viral polymerase that is …

The quest for effective drugs to treat COVID-19 has been a priority since the outbreak of the
disease. The clinical application of remdesivir has been greatly restricted by the need for …

Abstract Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia with an unusual
outbreak in Wuhan, China, which is caused by severe acute respiratory syndrome …

Vaccines and antivirals are the classical weapons deployed to contain, prevent, and treat life-
threatening viral illnesses. Specifically, for SARS-CoV-2 infection, vaccines protect against …

Nirmatrelvir–ritonavir (Paxlovid [Pfizer]) is used as first-line therapy for nonhospitalized
persons with Covid-191 on the basis of the results of the Evaluation of Protease Inhibition for …

Although vaccines are available for SARS-CoV-2, antiviral drugs such as nirmatrelvir are still
needed, particularly for individuals in whom vaccines are less effective, such as the …